Current and future trends in magnetic resonance imaging assessments of the response of breast tumors to neoadjuvant chemotherapy.
The current state-of-the-art assessment of treatment response in breast cancer is based on the response evaluation criteria in solid tumors (RECIST). RECIST reports on changes in gross morphology and divides response into one of four categories. In this paper we highlight how dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted MRI (DW-MRI) may be able to offer earlier, and more precise, information on treatment response in the neoadjuvant setting than RECIST. We then describe how longitudinal registration of breast images and the incorporation of intelligent bioinformatics approaches with imaging data have the potential to increase the sensitivity of assessing treatment response. We conclude with a discussion of the potential benefits of breast MRI at the higher field strength of 3T. For each of these areas, we provide a review, illustrative examples from clinical trials, and offer insights into future research directions.
Department of Radiology and Radiological Sciences, Institute of Imaging Science, Nashville, TN 37232-2310, USA.
Lori R
LR
Arlinghaus
Xia
X
Li
Mia
M
Levy
David
D
Smith
E Brian
EB
Welch
John C
JC
Gore
Thomas E
TE
Yankeelov